- Report
- August 2025
- 185 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Report
- August 2025
- 195 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Report
- April 2025
- 175 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- October 2025
- 250 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- September 2025
- 250 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- September 2025
- 250 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- September 2025
- 250 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- September 2025
- 287 Pages
Global
From €5109EUR$5,850USD£4,438GBP
- Drug Pipelines
- April 2025
- 280 Pages
Global
From €2620EUR$3,000USD£2,276GBP
- Clinical Trials
- April 2025
- 180 Pages
Global
From €2620EUR$3,000USD£2,276GBP
- Clinical Trials
- April 2025
- 150 Pages
Global
From €1747EUR$2,000USD£1,517GBP
- Report
- October 2024
- 200 Pages
Global
From €3275EUR$3,750USD£2,845GBP
- Report
- January 2025
- 180 Pages
Global
From €3930EUR$4,500USD£3,414GBP
- Report
- June 2025
- 400 Pages
Global
From €4322EUR$4,949USD£3,755GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2436EUR$2,789USD£2,116GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2436EUR$2,789USD£2,116GBP
- Report
- June 2025
- 200 Pages
Global
From €2436EUR$2,789USD£2,116GBP
- Report
- February 2022
- 360 Pages
United States
From €3144EUR$3,600USD£2,731GBP
- Report
- March 2021
- 240 Pages
United States
From €2620EUR$3,000USD£2,276GBP
- Report
- January 2023
- 189 Pages
Global
From €3668EUR$4,200USD£3,186GBP
Ramucirumab is a monoclonal antibody used in the treatment of certain types of cancer. It is used in combination with other drugs to treat metastatic gastric cancer, metastatic non-small cell lung cancer, and metastatic colorectal cancer. It works by blocking the action of a protein called vascular endothelial growth factor (VEGF), which helps cancer cells grow and spread. Ramucirumab is approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Ramucirumab is a relatively new drug in the oncology market, but it has been gaining traction in recent years. It is used in combination with other drugs to treat a variety of cancers, and it has been shown to be effective in prolonging survival in some patients. It is also being studied in combination with other drugs for the treatment of other types of cancer.
Some of the companies in the Ramucirumab market include Eli Lilly, AstraZeneca, Merck, and Pfizer. Show Less Read more
